Search Results for "Zofran"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Zofran. Results 1 to 4 of 4 total matches.
See also: ondansetron
Figure 1: Treatments for Irritable Bowel Syndrome (IBS) in Adults (online only)
The Medical Letter on Drugs and Therapeutics • Feb 03, 2025 (Issue 1721)
Pain
IBS-C
IBS-D Zofran eluxadoline Viberzi alosetron Lotronex probiotics ondansetron Xifaxan ...
View Figure: Treatments for Irritable Bowel Syndrome (IBS) in Adults
Med Lett Drugs Ther. 2025 Feb 3;67(1721):e1 doi:10.58347/tml.2025.1721c | Show Introduction Hide Introduction
Comparison Chart: Safety of Drugs for IBS in Pregnancy and Lactation (online only)
The Medical Letter on Drugs and Therapeutics • Feb 03, 2025 (Issue 1721)
in breast milk
Ondansetron (Zofran) ▶ Majority of data suggest no increased risk of congenital ...
View the Comparison Chart: Safety of Drugs for IBS in Pregnancy and Lactation
Med Lett Drugs Ther. 2025 Feb 3;67(1721):e1-2 doi:10.58347/tml.2025.1721b | Show Introduction Hide Introduction
Onapgo — An Apomorphine Subcutaneous Infusion for Parkinson's Disease
The Medical Letter on Drugs and Therapeutics • Jul 21, 2025 (Issue 1733)
antagonists
such as ondansetron (Zofran, and others) can cause
severe hypotension and loss of consciousness ...
Onapgo (Supernus), a solution for continuous
subcutaneous infusion containing the dopamine
agonist apomorphine, has been approved by the FDA
for treatment of motor fluctuations in adults with
advanced Parkinson's disease (PD). Subcutaneously
injected apomorphine (Apokyn, and generics) has
been available for intermittent use for years. Vyalev, a
foscarbidopa/foslevodopa solution for subcutaneous
infusion, was approved in 2024 for the same indication.
Med Lett Drugs Ther. 2025 Jul 21;67(1733):116-8 doi:10.58347/tml.2025.1733d | Show Introduction Hide Introduction
Drugs for Irritable Bowel Syndrome
The Medical Letter on Drugs and Therapeutics • Feb 03, 2025 (Issue 1721)
(Zofran, and generics), a 5-HT3 receptor
antagonist, is FDA-approved for prevention of
chemotherapy ...
Irritable bowel syndrome (IBS) is a common disorder
characterized by recurrent abdominal pain and altered
bowel habits, often accompanied by bloating. IBS
is classified by its predominant bowel symptom:
constipation (IBS-C), diarrhea (IBS-D), mixed type
(IBS-M), or unclassified (IBS-U). Since the exact cause
of IBS is unknown, the goal of treatment is symptom
control. Some over-the-counter (OTC) products and
prescription drugs for IBS are listed in Tables 1-4. The
safety of these drugs during pregnancy and lactation
is described in Table 5 (online only).
Med Lett Drugs Ther. 2025 Feb 3;67(1721):17-24 doi:10.58347/tml.2025.1721a | Show Introduction Hide Introduction